May 2nd 2023
Each month, our editorial staff compiles a recap of the top news in cardiology from the past month. Our April 2023 month in review features new data and documents related to heart failure management, recaps and forecasts of top regulatory decisions, and other top news!
Experts' Perspective: Top Cardiology News from ACC 23March 10th 2023
With ACC 2023 in the rearview, the HCPLive editorial team compiled perspectives on the meeting’s top piece of news from half a dozen clinicians specializing in various subspecialties across the spectrum of cardiovascular care.
Deepak Bhatt, MD, MPH: ENTRIGUE Results Inform Pegozafermin's Potential in Severe HypertriglyceridemiaMarch 8th 2023
Deepak Bhatt, MD, MPH, discusses results of the phase 2 ENTRIGUE trial and how it informs clinicians on the effects of the human FGF21 analogue in patients with severe hypertriglyceridemia.
Bempedoic Acid Reduces Risk of MACE by 13%, But Proves No Benefit on Cardiovascular DeathMarch 4th 2023
Results of the CLEAR Outcomes trial suggests adherence to bempedoic acid was associated with a 13% relative reduction in incidence of the trial's primary endpoint of 4-point MACE, but no benefit was observed for risk of cardiovascular death or all-cause mortality in the trial.
Despite Improved Screening and Rates of Dyslipidemia, Prescribing Not Yet at Optimal levelsJanuary 13th 2023
An analysis of NHANES data from 1999-2018 details the progress made with regard to cholesterol management on a population level but also provides insight into areas where room for improvement still exists.
Exposure to Statin Therapy Could Lower Risk of Brain Bleeds in Older PatientsDecember 9th 2022
Data from an analysis of patients in Denmark provides an overview of the effects of statin therapy on risk of intracerebral hemorrhage, with insights into how this benefit may vary based on the location of the intracerebral hemorrhage.
CLEAR Outcomes: Bempedoic Acid Reduces Cardiovascular EventsDecember 7th 2022
Almost 3 years after approval, Esperion's announcement of positive results from the CLEAR Outcomes trial indicate bempedoic acid is the first oral non-statin therapy to meet the MACE-4 primary endpoint included in the outcomes trial of the ATP citrate lyase inhibitor.
Extending Anticoagulation with Rivaroxaban After DVT Could Further Reduce Recurrent Thrombosis RiskNovember 25th 2022
Results of the RIDTS study suggest extending anticoagulation with rivaroxaban to 12 weeks as opposed to the traditional 6-week course could reduce recurrent venous thromboembolism in patients with symptomatic isolated DVT.
Vitamin D Supplementation Does Not Prevent Statin-Associated Muscle Pain or Reduce DiscontinuationNovember 24th 2022
An analysis of statin initiators within the VITAL trial provides insight into the impact of vitamin D supplementation on the incidence of statin-associated muscle symptoms and statin discontinuation among participants in the trial.
Despite Advances, Room for Improvement in Anticoagulation Exists for Older AdultsNovember 21st 2022
An analysis of data from Medicare beneficiaries receiving treatment over a decade-long period provides a snapshot of oral anticoagulation initiation and nonadherence among older patients with atrial fibrillation in the US.
Almost 1 in 3 High-Risk AFib Patients Not Receiving AnticoagulationNovember 17th 2022
Using data from 88 medical centers across the US, new data is providing clinicians with an overview of contemporary trends in DOAC and warfarin use in adult patients with nonvalvular atrial fibrillation at high risk for stroke over the past decade.
Study Proves Feasibility of Entirely Remote Management of Hypertension, Cholesterol DisordersNovember 10th 2022
A 10,000-person study provides insight into the feasibility and effectiveness of participation an entirely remote hypertension and lipid management program in a diverse health care network.
SPORT: Supplements Fail to Lower LDL-C in Primary Prevention PopulationNovember 8th 2022
Erin Michos, MD, provides further insight in an on-site interview AHA 22 related to results of the SPORT trial, which provide direct comparative insights into the impact of several dietary supplements and placebo therapy relative to low-dose statin therapy in a primary prevention cohort.
Edoxaban Could Safely Reduce Risk of Thromboembolism in Pediatric Patient PopulationsNovember 4th 2022
Data from a phase 3 trial presented at AHA 22 suggests use of edoxaban could be a safe and effective method for reducing risk of thromboembolism in pediatric patients with cardiovascular disease considered to be at increased risk of thrombosis.
Minority Patients with AFib Less Likely to Receive Oral Anticoagulation than White CounterpartsOctober 28th 2022
An analysis of the GWTG-Atrial Fibrillation Registry data suggests Black patients with AFib were 25% less likely to receive a prescription for oral anticoagulation at discharge and 27% less likely to receive a DOAC than their non-Hispanic White counterparts.
Preexisting Statin Use Linked to Lower COVID-19 SeverityOctober 24th 2022
An analysis of electronic medical record data from more than 140k patients hospitalized at 185 medical centers in the US provides insight into associations between preexisting statin use and reduced risk of severe disease in COVID-19.
Claims Data Compares Safety, Effectiveness of Apixaban vs Rivaroxaban in AFib and Valvular Heart DiseaseOctober 18th 2022
An analysis of claims data from a 7-year period provides insight into the rate of ischemic stroke or systemic embolism and bleeding events with 2 popular DOACs in people with atrial fibrillation and valvular heart disease.
Study Details Gaps in Diagnosis for Homozygous Familial Hypercholesterolemia in the USOctober 12th 2022
An analysis of the CASCADE FH Registry provides insight into differences in patient characteristics and outcomes among those with homozygous familial hypercholesterolemia enrolled in the registry as children and those enrolled in the registry as adults.
Rethinking Statins: Time for Primordial Prevention?September 27th 2022
Statins and their specific role have been the subject of debate for years. In this feature, 6 leading experts in cardiometabolic health share their perspectives on whether statins should be used in the sense of primordial prevention for ASCVD.
Network Meta-Analysis Details Comparative Efficacy of Nonstatin Lipid-Lowering AgentsSeptember 23rd 2022
A meta-analysis of 48 randomized controlled trials provides clinicians with insight into the comparative efficacy profiles of multiple nonstatin LDL-lowering agents when added to maximally tolerated statin therapy.
Statin Muscle Symptom Risk Overblown, Does Not Outweigh CV Benefits, CTT Study ShowsAugust 29th 2022
Results of a CTT meta-analysis from ESC Congress 22 detail the excess risk of muscle symptoms observed with statin therapy from more than 20 clinical trials assessing statins against placebo or less intensive statin therapy.
PANTHER: P2Y12 Monotherapy Bests Aspirin for Secondary Prevention in Coronary Artery DiseaseAugust 29th 2022
The PANTHER study, which was a meta-analysis of 7 RCTs comparing P2Y12 inhibitor monotherapy against aspirin for secondary prevention in CAD, suggests use of P2Y12 inhibitor monotherapy was associated with a 12% reduction in risk of the primary composite endpoint, with a 23% relative reduction in risk of myocardial infarction.
Milvexian Shows Promise for Preventing Stroke in Phase 2 Dose-Finding TrialAugust 28th 2022
A phase 2 dose-finding trial presented at ESC Congress 22 suggests the use of milvexian could reduce the risk of ischemic stroke by up to 30% without a major increase in the risk of bleeding events in certain doses.
Cardiology Month in Review: August 2022August 27th 2022
Our cardiology month in review spotlights the most popular content from the past month. The top content from August 2022 includes new antithrombotic guidance from CHEST, USPSTF recommendation statement on statin use in primary prevention, and coverage of ESC 22, including DELIVER, TIME, and other late-breaking data.